From what I understand, the cock up was not escrowing more seed holders - especially suppliers and investors with an axe to grind that got in at low levels.
Who cares about the chairman - he is non-exec, what matters is the CEO and his determination to succeed to turn the ship around. If they can keep the sales momentum going and turn a profit in Australia in 2022 then fundamentals will drive any re-rate (hopefully).
This whole probiotic space is taking off and good products, with strong distribution channels and solid niches can thrive.
I wouldn't catch a falling knife so the only thing to do is let the market find a clearing level, the overhang will get depleted and eventually clear so that future re-rates are driven by forward earnings potential not seed scrambling to exit ...
Haha...The worst ipo in the 2021..., page-86
-
- There are more pages in this discussion • 20 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BIO (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
72.5¢ |
Change
0.065(9.85%) |
Mkt cap ! $156.1M | |||
| Open | High | Low | Value | Volume |
| 67.0¢ | 72.5¢ | 66.5¢ | $1.084M | 1.544M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 88888 | 72.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 72.5¢ | 58624 | 1 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| BIO (ASX) Chart |